



NUCLEAR MEDICINE

WORLD MARKET REPORT & DIRECTORY

RADIONUCLIDES, RADIOPHARMACEUTICALS,
MARKET PIPELINE AND R&D PORTFOLIO,
MARKET DATA, PRODUCT PRICING, COMPANIES PROFILES

EDITION 2016

Nuclear Medicine

Edition 2016

NUCLEAR MEDICINE WORLD MARKET REPORT AND DIRECTORY-2016

A 990-PAGE DOCUMENT THAT PROVIDES AN EXHAUSTIVE DESCRIPTION AND ANALYSIS OF OVER 370 RADIOPHARMACEUTICALS AND RADIONUCLIDES WITH A COMPREHENSIVE PROFILE OF MORE THAN 170 COMPANIES AND INSTITUTIONS ACTIVE IN THE RADIOPHARMACEUTICALS INDUSTRY.

This third edition will once again advise the radiopharmaceutical industry, investment organizations, international consulting firms, R&D laboratories to understand the market, the competitive environment, the technology development in this field as well as the potential of merger and acquisitions (M&A).

MEDDraysintell considers 2016 to be the pivotal year for the nuclear medicine industry.

MEDDraysintell estimated the global market for nuclear medicine (radiopharmaceuticals) at US\$ 4.3 billion in 2015, growing by just over 2% a year between 2013 and 2015. While it has been stable last year, this market is expected to climb to US\$ 25 billion by 2030. This slow growth shown in 2013-2015 is primarily driven by lower revenues from technetium-99m related products and an unfavorable impact from US\$ exchange rates versus major currencies. This slow progression is compensated by a robust increase of the radiotherapeutics which have grown by about 60% a year from 2013 to 2015. Without this exchange rate influence, MEDDraysintell estimates that the nuclear medicine market would have reached over US\$ 4.7 billion in 2015, thereby exhibiting an annual growth of more than 7% for the period 2013-2015.

MEDDraysintell considers the year 2016 to be the pivotal year in the development of the nuclear medicine industry, shifting from a market centered on radiodiagnostics to a business driven by radiotherapeutics, with a product like Xofigo (Bayer) showing a blockbuster profile and the upcoming launch of new radiotherapeutics with high revenue potential such as Lutathera (Advanced Accelerator Applications). Other radiotherapeutics will penetrate the market later in the decade also labeled with Lu-177. The year 2016 is also the turning point for the introduction of new proprietary fluorinated molecules and novel radiodiagnostics based on Ga-68. Innovative solutions and additional sources will also emerge to cover the need for molybdenum-99. Finally with an increasing interest from the conventional pharmaceutical industry and institutional investors, mergers and acquisitions activity will accelerate.

The world nuclear medicine market is fragmented, with 72 companies selling on regular basis radiopharmaceuticals. However, three companies are controlling almost half of the world market, whereas a large group 61 companies are sharing almost 16% of it. Nuclear medicine is not a recent science, but the past years saw the emergence of new radionuclides and over 35 companies are involved in research and development, but not yet selling radiopharmaceuticals.

Opportunities exist for larger groups or investors to finance such development, to merge with key partners and/or to acquire companies.

Tables of Contents

Nuclear Medicine World Market Report

A detailed table of contents of this report is available upon request.

Chapters / Sections

Executive Summary (Pages 29 to 42)

Nuclear Medicine Market (Pages 43 to 63)

- General
 - Nuclear medicine procedures
 - Market size and shares
 - Major nuclear medicine products
 - The S-Curve of nuclear medicine and Market Matrix
-

Radionuclides (Pages 64 to 253)

- General considerations
 - Radionuclide characteristics
 - Radionuclides of interest
 - Process of selection
 - Radionuclide selection
 - Radionuclides and nuclear medicine modalities
 - Classification by primary radiation type
 - Gamma (γ) emitters
 - Positron (β^+) emitters
 - Beta (β^-) emitters
 - Alpha (α) emitters
 - Conversion electron emitters
 - Auger electron emitters
 - Summarized radionuclide tables
 - Commercial interest
 - Production routes
 - Radionuclide prices
 - Source of radionuclides (Country/Regional basis)
 - Specific manufacturing and handling constraints
 - Manufacturing tools
 - The PET manufacturing network: the fluorine-18 contradictions
 - Issue of radioactive waste
 - Radionuclides
 - A detailed description of 44 radionuclides from Actinium 225 (^{225}Ac) to Zirconium 89 (^{89}Zr) which have led to an application in nuclear medicine in the form of a marketed tracer or marketed drug, or are involved in a molecule that is already under clinical development. Description includes physical properties, manufacturing route, major product based on the radionuclide, source and availability, price, issues and comments.
 - Generators
 - A detail description of nine generators from Actinium 225 (^{225}Ac) – $^{225}\text{Ac}/^{213}\text{Bi}$ generator to Zinc 62 (^{62}Zn) – $^{62}\text{Zn}/^{62}\text{Cu}$ generator. Description includes physical properties, manufacturing route, source and availability, price, issues and comments.
 - This chapter also includes a complete section about the Molybdenum shortage issue.
 - Radionuclides for R&D
 - A description including another 46 radionuclides presently used in R&D.
-

Tables of Contents

Nuclear Medicine World Market Report

Chapters / Sections

Radiopharmaceuticals on the Market (Pages 254 to 438)

- General
 - Vectors
 - Salts
 - Particles
 - Cells and human proteins
 - Small molecules
 - Antibodies
 - Indications
 - Oncology
 - Cardiology
 - Neurology
 - Miscellaneous
 - Radiopharmaceutical sales prices
 - Radiodiagnostics agents
 - Radiotherapeutic agents
 - Marketed Radiopharmaceuticals
 - A comprehensive description of 96 radiopharmaceuticals available on the market, from ^{11}C -Choline (^{11}C -CH) to ^{223}Ra -Radium Dichloride. Each radiopharmaceutical section includes a complete description with the chemical name, official name, owner, clinical applications, availability and price, competition and comments.
 - Discontinued Radiopharmaceuticals
 - A succinct description including 22 discontinued major radiopharmaceuticals, and the explanation for their market withdrawal.
-

Radiopharmaceuticals under development (Pages 439 to 657)

- General considerations
 - Radiopharmaceutical Development
 - Clinical development
 - Development costs
 - Drugs under development
 - Oncology – Molecules targeting specific biological mechanisms
 - Oncology – Molecules targeting specific tumors
 - Cardiology
 - Neurology
 - Miscellaneous
 - Radiopharmaceuticals under clinical development
 - A comprehensive review of 133 radiopharmaceuticals under development, describing the molecules that have been explored through clinical trials and injected at least once in a human being and for which data have been reported. The review includes a complete description of the product, clinical applications, stage of development and comments. The list goes from ^{18}F -AraG to ^{225}Ac -Lintuzumab.
 - Discontinued or on hold radiopharmaceuticals
 - A review of 23 well-known products, in particular the molecules that have got a brand name, the ones that have reached clinical Phase III and those that have been under development for a long time, which were expected by the nuclear medicine community, but failed.
-

Tables of Contents

Nuclear Medicine World Market Report

Chapters / Sections

Radiopharma Suppliers (*Pages 658 to 899*)

- General
 - Geographical origin of suppliers and development companies
 - Private companies
 - A comprehensive profile of 100 private companies producing radiopharmaceuticals on a regular basis (PET, SPECT or radiotherapeutic products). Each profile includes a company description and key executives, financial data including revenue in nuclear medicine, radiopharmaceutical products marketed, projects in nuclear medicine and comments. The list goes from ACOM to Zevacor Pharma.
 - Public Institutions
 - A comprehensive profile of 28 public institutions supplying radiopharmaceuticals on a regular basis. Each profile includes a company description, radiopharmaceutical products marketed, projects in nuclear medicine and comments.
-

Radiopharma Development Companies – R&D (*Pages 900 to 972*)

- General
 - Company descriptions
 - A comprehensive profile of 44 companies currently doing research and development on one or more radiopharmaceuticals from their own pipeline, but have not yet marketed a radiopharmaceutical product. Each profile includes a company description, financial data, a list of radiopharmaceutical development projects and comments. The list goes from 3B Pharmaceuticals to Willex AG.
-

Glossary

Abbreviations

Contacts

How to Subscribe

To request a detailed table of contents of this report and to order, please send an e-mail with your contact details to: peg@medraysintell.com

Price: EUR 7,000

About MEDraysintell

Strategic intelligence for the radiation healthcare

Bringing value to Businesses and Investors!

MEDraysintell is a team of international experts providing first-rate strategic intelligence in nuclear medicine, radiotherapy, proton therapy and brachytherapy.

We offer the most comprehensive set of reports and directories, with over 1,800 pages of unrivaled intelligence covering some of the most exciting healthcare technologies using radiation for diagnosis and treatment.

We offer client-specific intelligence in the field of radiation healthcare, with the upmost knowledge leveraging our extended network of worldwide contacts.

We are proud to support numerous companies globally, helping them better understand the markets, competitive environment as well as the potential of merger and acquisitions (M&A) and technology development. We have repeat satisfied clients operating in the field of medical radiation, investment banks and institutional investors, large international consulting firms and universities research laboratories.

MEDraysintell was created in 2013 by Paul-Emmanuel Goethals and Richard Zimmermann. It combines over 40 years of experience in radiation healthcare.

www.medraysintell.com

Contacts:

For general enquiries, please e-mail at contact@medraysintell.com

Paul-Emmanuel Goethals, MBA

Louvain-la-Neuve, Belgium

peg@medraysintell.com

Phone: +32 491 080 968

Dr. Richard Zimmermann, PhD

Lalaye, France

rz@medraysintell.com

Phone: +33 6 82 80 06 00